Valiant Laboratories posts Q3 FY26 results: Standalone Profit at ₹3.30 Crore, Consolidated Loss at ₹7.06 Crore
Valiant Laboratories reported standalone net profit of ₹3.30 crore for Q3 FY26, down from ₹16.00 crore year-on-year. Consolidated net loss for the quarter was ₹7.06 crore. The company's Board of Directors approved the audited financial results on February 11, 2026.
The reported decline in profitability and the shift to a consolidated loss could impact investor sentiment and the company's valuation.
The company reported a significant decline in standalone profit and a shift to a consolidated net loss, indicating a negative financial performance compared to the previous year.
Valiant Laboratories Limited announced its audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors considered and approved these results on February 11, 2026.
For the quarter ended December 31, 2025, the company reported a standalone net profit of ₹3.30 crore. This compares to a standalone net profit of ₹16.00 crore in the same quarter of the previous year. For the nine-month period ended December 31, 2025, the standalone net profit was ₹20.15 crore, a decrease from ₹53.88 crore in the corresponding period of the prior year.
On a consolidated basis, Valiant Laboratories reported a net loss of ₹705.62 lakh (₹7.06 crore) for the quarter ended December 31, 2025. This is a significant change from a consolidated net profit of ₹23.85 crore in the same quarter of the previous year. For the nine-month period ended December 31, 2025, the consolidated net loss stood at ₹503.52 lakh (₹5.04 crore), compared to a consolidated net profit of ₹290.51 lakh (₹2.91 crore) in the corresponding period of the prior year.
The Board Meeting, which commenced at 02:00 P.M. and concluded at 04:30 P.M., also took on record the audit report issued by the statutory auditor, Raman S. Shah & Co., Chartered Accountants. The financial results will be available on the company's website, www.valiantlabs.in, as well as on the websites of BSE Limited and NSE Limited.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.